A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
Public ClinicalTrials.gov record NCT02133742. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1B, OPEN LABEL, DOSE FINDING STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AXITINIB (AG-013736) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH ADVANCED RENAL CELL CANCER
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Despite substantial improvements of patients outcome in advanced RCC, durable and complete response is uncommon. The majority of patients eventually develop resistance and exhibit disease progression. Combining a PD-1 inhibitor, which has shown single-agent efficacy with axitinib may provide additional clinical benefit compared to axitinib alone.
Study identification
- NCT ID
- NCT02133742
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 52 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 16, 2014 (Actual)
- Primary completion
- Mar 31, 2017 (Actual)
- Completion
- Jul 3, 2019 (Actual)
- Last update posted
- Jul 28, 2021
2014 – 2019
United States locations
- U.S. sites
- 19
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| H. Lee Moffitt Cancer Center & Research Institute, Inc. | Tampa | Florida | 33612 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Brigham & Women's Hospital | Boston | Massachusetts | 02115 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Attn. Alicia Sammarco, RPh, NYU Investigational Pharmacy | New York | New York | 10016 | — |
| NYU Langone Medical Center | New York | New York | 10016 | — |
| NYU Langone | New York | New York | 10016 | — |
| Investigational Drug Services | Columbus | Ohio | 43210 | — |
| James Cancer Hospital | Columbus | Ohio | 43210 | — |
| The Ohio State University Brain and Spine Hospital | Columbus | Ohio | 43210 | — |
| Martha Morehouse Medical Plaza | Columbus | Ohio | 43221 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Henry-Joyce Cancer Clinic | Nashville | Tennessee | 37232 | — |
| Vanderbilt Oncology Pharmacy | Nashville | Tennessee | 37232 | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02133742, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 28, 2021 · Synced Oct 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02133742 live on ClinicalTrials.gov.